Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 3, 2014, Pages 305-311

  Seaton, R A ^a   Johal, S ^b   Coia, J E ^c   Reid, N ^d   Cooper, S ^e   Jones, B L ^c  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b RTI HEALTH SOLUTIONS   (United States)

^c NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^d NHS AYRSHIRE AND ARRAN   (United Kingdom)

^e PH ASSOCIATES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; LINEZOLID; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; COST CONTROL; DRUG MONITORING; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIDDLE AGED; OUTPATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL INFECTION; TREATMENT DURATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; SCOTLAND; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; YOUNG ADULT;

EID: 84896721181     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1956-z     Document Type: Article

References (29)

1. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y (2005) The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26:166-174
2. Melzer M, Eykyn SJ, Gransden WR, Chinn S (2003) Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 37:1453-1460
3. Engemann JJ, Carmeli Y, Cosgrove SE et al (2003) Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36:592-598
4. Goetghebeur M, Landry PA, Han D, Vicente C (2007) Methicillin-resistant Staphylococcus aureus: A public health issue with economic consequences. Can J Infect Dis Med Microbiol 18:27-34
5. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM (2006) Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 144:309-317
6. Wier LM, Henke R, Friedman B (2010) Diagnostic groups with rapidly increasing costs, by payer, 2001-2007. HCUP Statistical Brief #91. June 2010. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. Available online at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb91.pdf
7. Personal correspondence Matthew Armstrong, Principle Information Analyst, NHS National Services Scotland
8. Gould FK, Brindle R, Chadwick PR et al (2009) Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 63:849-861
9. Dryden M, Andrasevic AT, Bassetti M et al (2010) A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin Microbiol Infect 16(Suppl 1):3-30
10. Seaton RA, Sharp E, Bezlyak V, Weir CJ (2011) Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Chemother 38:243-248
11. Department of Health Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) (2011) Antimicrobial Stewardship: "Start Smart - Then Focus (formally 25). Available online at: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/documents/ digitalasset/dh-131181.pdf
12. Chapman ALN, Seaton RA, Cooper MA et al (2012) Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother 67:1053-1062
13. Dryden M, Saeed K, Townsend R et al (2012) Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother 67:2289-2296
14. Nathwani D, Morgan M, Masterton RG et al (2008) Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 61:976-994
15. Lamont E, Seaton RA, Macpherson M, Semple L, Bell E, Thomson AH (2009) Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother 64:181-187
16. Martone WJ, Lindfield KC, Katz DE (2008) Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract 62:1183-1187
17. Chapman ALN, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD (2009) Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother 64:1316-1324
18. NHS reference costs 2007-08. Available online at: http://webarchive. nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-098945
19. Curtis L (2008) Unit costs of health and social care. Personal Social Services Research Unit, University of Kent, UK
20. British Medical Association and Royal Pharmaceutical Society (2010) British National Formulary 59. British Medical Journal Publishing Group and Pharmaceutical Press, London
21. De Cock E, Sorensen S, Levrat F et al (2009) Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France. Med Mal Infect 39:330-340
22. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C; Linezolid CSSTI Study Group (2005) Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49:2260-2266
23. Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM (2012) Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. Clin Ther 34:1667-1673.e1
24. Bounthavong M, Hsu DI (2010) Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin 26:407-421
25. Gray A, Dryden M, Charos A (2012) Antibiotic management and early discharge from hospital: an economic analysis. J Antimicrob Chemother 67:2297-2302
26. Seaton RA, Bell E, Gourlay Y, Semple L (2005) Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother 55:764-767
27. Health Protection Scotland (2013) Quarterly report on the surveillance of Staphylococcus aureus bacteraemias in Scotland, July-September 2012. Available online at: http://www.hps.scot.nhs.uk/haiic/sshaip/wrdetail.aspx?id= 53734&wrtype=9
28. Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S (2009) Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 15:125-136
29. Costs book 2009 (Scotland). Available online at: http://isdscotland.org/ isd/3632.html